Risk Stratification in Chronic Lymphocytic Leukemia
The Role of the Clinical Laboratory
Risk Assessment

November 2008
To summarize, when a patient with potential CLL comes to the laboratory, think of it as a three-step process.
First of all, the diagnosis is made based on the peripheral blood CBC and differential count as well as the immunophenotype.
Second, risk assessment based on clinical, hematology, immunophenotyping and genetic and molecular studies.
Finally, assessing outcome post-therapy based on immunophenotype, potential immunohistochemistry and certainly clinical and MRI staging.
Today we have tried to cover this middle segment, or risk assessment.
Risk Assessment |
Jump to section:
- Introduction
- Goals Today
- Risk Assessment
- Risk Assessment in CLL
- CLL Rai Stage: Treatment Free
- CLL: Nodular Pattern of BM Infiltration
- CLL: Pattern of BM Infiltration
- Blood: Prognostic Indicators
- CLL and Fragile Cells
- CLL: Fragile Cells and Time to Treatment
- CLL Prognostics: CD38
- CLL Rai Stage 0: CD38
- ZAP-70 in B-CLL
- ZAP-70 in B-CLL: Detection
- ZAP-70 in B-CLL: Questions
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70: Immunohistochemistry
- CLL Rai Stage 0: ZAP-70
- CD49d in CLL
- CD49d: Clinical Role
- Time to Treatment (TTT) & Overall Survival (OS) from Diagnosis*
- CD49d in CLL
- CD49d in CLL
- Immunoglobulin Variable (IgVH) Region Mutation Status
- IgVH Sequencing
- CLL Rai Stage 0: IgVH
- Chromosome Anomalies in Chronic Lymphocytic Leukemia
- Distribution of Chromosome Anomalies in CLL Detected by FISH
- 13q-: A Microdeletion in B-CLL
- Overall Survival: By FISH Anomaly
- Risk Assessment in CLL: Summary
- Risk Assessment In CLL
- Risk Assessment
- Goals Today
- Questions?